BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34906772)

  • 21. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR‑92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.
    Liu F; Sang M; Meng L; Gu L; Liu S; Li J; Geng C
    Int J Oncol; 2018 Oct; 53(4):1505-1515. PubMed ID: 30066891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
    Zheng S; Houseman EA; Morrison Z; Wrensch MR; Patoka JS; Ramos C; Haas-Kogan DA; McBride S; Marsit CJ; Christensen BC; Nelson HH; Stokoe D; Wiemels JL; Chang SM; Prados MD; Tihan T; Vandenberg SR; Kelsey KT; Berger MS; Wiencke JK
    Neuro Oncol; 2011 Mar; 13(3):280-9. PubMed ID: 21339190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA PVT1 indicates a poor prognosis of glioma and promotes cell proliferation and invasion via target EZH2.
    Yang A; Wang H; Yang X
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29046366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
    Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
    Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long noncoding RNA DLGAP1-AS1 promotes the progression of glioma by regulating the miR-1297/EZH2 axis.
    Liu L; Li X; Shi Y; Chen H
    Aging (Albany NY); 2021 Apr; 13(8):12129-12142. PubMed ID: 33901010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacological and biological importance of EZH2 signaling in lung cancer.
    Entezari M; Taheriazam A; Paskeh MDA; Sabouni E; Zandieh MA; Aboutalebi M; Kakavand A; Rezaei S; Hejazi ES; Saebfar H; Salimimoghadam S; Mirzaei S; Hashemi M; Samarghandian S
    Biomed Pharmacother; 2023 Apr; 160():114313. PubMed ID: 36738498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
    Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
    Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3 target gene profile highlights differences between low- and high-grade astrocytic tumors.
    Sharma V; Malgulwar PB; Purkait S; Patil V; Pathak P; Agrawal R; Kulshreshtha R; Mallick S; Julka PK; Suri A; Sharma BS; Suri V; Sharma MC; Sarkar C
    Carcinogenesis; 2017 Feb; 38(2):152-161. PubMed ID: 27993893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circ-EZH2 knockdown reverses DDAH1 and CBX3-mediated cell growth and invasion in glioma through miR-1265 sponge activity.
    Gao F; Du Y; Zhang Y; Ren D; Xu J; Chen D
    Gene; 2020 Feb; 726():144196. PubMed ID: 31669648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
    Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
    Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of the EZH2/miRNA/β-catenin signaling suppresses aerobic glycolysis in glioma.
    Wang Y; Wang M; Wei W; Han D; Chen X; Hu Q; Yu T; Liu N; You Y; Zhang J
    Oncotarget; 2016 Aug; 7(31):49450-49458. PubMed ID: 27385092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
    Eich ML; Athar M; Ferguson JE; Varambally S
    Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
    Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
    Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
    Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
    Smits M; Nilsson J; Mir SE; van der Stoop PM; Hulleman E; Niers JM; de Witt Hamer PC; Marquez VE; Cloos J; Krichevsky AM; Noske DP; Tannous BA; Würdinger T
    Oncotarget; 2010 Dec; 1(8):710-20. PubMed ID: 21321380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-506-3p inhibits colorectal cancer cell proliferation through targeting enhancer of zeste homologue 2.
    Ai L; Luo X; Yan X; Jiang S
    Bioengineered; 2021 Dec; 12(1):4044-4053. PubMed ID: 34288823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
    Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
    J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.